{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:50:31Z","timestamp":1778637031562,"version":"3.51.4"},"reference-count":20,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1248\/bpb.b22-00164","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T22:12:38Z","timestamp":1659305558000},"page":"1203-1207","source":"Crossref","is-referenced-by-count":5,"title":["Intracerebroventricular Administration of Dermorphin-Dynorphin Analogs Producing Antidepressant-Like Effects through Activation of \u03bc&lt;sub&gt;1&lt;\/sub&gt;- and \u03ba-Opioid Receptors in Mice"],"prefix":"10.1248","volume":"45","author":[{"given":"Osamu","family":"Nakagawasai","sequence":"first","affiliation":[{"name":"Division of Pharmacology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ambo","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"},{"name":"Department of Pharmacology, School of Pharmacy, International University of Health and Welfare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Onogi","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"},{"name":"Faculty of Health Science, Tohoku Fukushi University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myu","family":"Okubo","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Tan-No","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Krishnan V, Nestler EJ. The molecular neurobiology of depression. <i>Nature<\/i>, <b>455<\/b>, 894\u2013902 (2008).","DOI":"10.1038\/nature07455"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Callaghan CK, Rouine J, O\u2019Mara SM. Potential roles for opioid receptors in motivation and major depressive disorder. <i>Prog. Brain Res.<\/i>, <b>239<\/b>, 89\u2013119 (2018).","DOI":"10.1016\/bs.pbr.2018.07.009"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nakagawasai O, Takahashi K, Ambo A, Onuma K, Takahashi N, Nemoto W, Tan-No K. Antidepressant effect of intracerebroventricularly administered deltorphin analogs in the mouse tail suspension test. <i>Biol. Pharm. Bull.<\/i>, <b>45<\/b>, 538\u2013541 (2022).","DOI":"10.1248\/bpb.b21-01078"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gav\u00e9riaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. <i>Nat. Genet.<\/i>, <b>25<\/b>, 195\u2013200 (2000).","DOI":"10.1038\/76061"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. <i>Trends Neurosci.<\/i>, <b>36<\/b>, 195\u2013206 (2013).","DOI":"10.1016\/j.tins.2012.11.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ide S, Fujiwara S, Fujiwara M, Sora I, Ikeda K, Minami M, Uhl GR, Ishihara K. Antidepressant-like effect of venlafaxine is abolished in \u03bc-opioid receptor-knockout mice. <i>J. Pharmacol. Sci.<\/i>, <b>114<\/b>, 107\u2013110 (2010).","DOI":"10.1254\/jphs.10136SC"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Wang Q, Long Y, Hang A, Zan GY, Shu XH, Wang YJ, Liu JG. The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel kappa agonist and mu partial agonist, in mice. <i>Psychopharmacology <\/i>(Berl.), <b>233<\/b>, 2411\u20132418 (2016).","DOI":"10.1007\/s00213-016-4292-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Braida D, Capurro V, Zani A, Rubino T, Vigan\u00f2 D, Parolaro D, Sala M. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. <i>Br. J. Pharmacol.<\/i>, <b>157<\/b>, 844\u2013853 (2009).","DOI":"10.1111\/j.1476-5381.2009.00230.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Archer S, Glick SD, Bidlack JM. Cyclazocine revisited. <i>Neurochem. Res.<\/i>, <b>21<\/b>, 1369\u20131373 (1996).","DOI":"10.1007\/BF02532378"},{"key":"10","unstructured":"10) Schwyzer R. How do peptides interact with lipid membranes and how does this affect their biological activity? <i>Braz. J. Med. Biol. Res.<\/i>, <b>25<\/b>, 1077\u20131089 (1992)."},{"key":"11","unstructured":"11) Ambo A, Sasaki Y. Dermorphin-dynorphin hybrid analogs: Opioid receptor selection and enzymatic stability. <i>Peptide Science\u2014Present and Future<\/i>. (Shimonishi Y ed.) Springer, Dordrecht (1999)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Moretti M, Ribeiro CM, Neis VB, Bettio LEB, Rosa PB, Rodrigues ALS. Evidence for the involvement of opioid system in the antidepressant-like effect of ascorbic acid. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, <b>391<\/b>, 169\u2013176 (2018).","DOI":"10.1007\/s00210-017-1446-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. <i>Br. J. Pharmacol.<\/i>, <b>124<\/b>, 669\u2013674 (1998).","DOI":"10.1038\/sj.bjp.0701882"},{"key":"14","unstructured":"14) Kelley AE, Bless EP, Swanson CJ. Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>278<\/b>, 1499\u20131507 (1996)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tejeda HA, Bonci A. Dynorphin\/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders. <i>Brain Res.<\/i>, <b>1713<\/b>, 91\u2013101 (2019).","DOI":"10.1016\/j.brainres.2018.09.023"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, Zani A, Gori E, Fratta W, Parolaro D, Sala M. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. <i>Biol. Psychiatry<\/i>, <b>63<\/b>, 286\u2013292 (2008).","DOI":"10.1016\/j.biopsych.2007.07.020"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Carlezon WA Jr, B\u00e9guin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>316<\/b>, 440\u2013447 (2006).","DOI":"10.1124\/jpet.105.092304"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Berrocoso E, Ikeda K, Sora I, Uhl GR, Sanchez-Blazquez P, Mico JA. Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. <i>Int. J. Neuropsychopharmacol.<\/i>, <b>16<\/b>, 151\u2013162 (2013).","DOI":"10.1017\/S1461145711001842"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Saigusa T, Aono Y, Waddington JL. Mechanisms underlying \u03b4- and \u03bc-opioid receptor agonist-induced increases in extracellular dopamine level in the nucleus accumbens of freely moving rats. <i>J. Oral Sci.<\/i>, <b>59<\/b>, 195\u2013200 (2017).","DOI":"10.2334\/josnusd.16-0874"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Brunton PJ, Russell JA. Attenuated hypothalamo-pituitary-adrenal axis responses to immune challenge during pregnancy: the neurosteroid opioid connection. <i>J. Physiol.<\/i>, <b>586<\/b>, 369\u2013375 (2008).","DOI":"10.1113\/jphysiol.2007.146233"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/8\/45_b22-00164\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:30:11Z","timestamp":1715232611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/8\/45_b22-00164\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b22-00164","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"b22-00164"}}